INTRODUCTION {#s1}
============

The checkpoint immunotherapy has been increasingly understood and used to unleash the immune system to fight against cancer \[[@R1]\]. These years, several immune checkpoints including CTLA-4 and PD-1/PD-L1 were identified and multiple agents have been developed to bind with the immunologic checkpoints and block checkpoint-pathways, which would otherwise impair the T cell anti-tumor activity. The efficacy of those agents in promoting immune recognition, enhancing the immune response with T cell and reducing the immune tolerance of tumor development has aroused tremendous enthusiasm in cancer treatment nowadays \[[@R2]\].

As one of the most critical checkpoint immunologic treatments, PD-1/PD-L1 blockade has become a promising focus of immunotherapy in cancer treatment \[[@R3]\]. Two antibodies targeting PD-1: nivolumab (Opdivo, Bristol-Myers Squibb, a fully human monoclonal IgG4 antibody), pembrolizumab (Keytruda, Merck, a humanized monoclonal IgG4 antibody) and an antibody against PD-L1 named atezolizumab (Roche, a fully humanized, engineered monoclonal antibody of IgG1 isotype) have been approved by US Food and Drug Administration (FDA) \[[@R3], [@R4]\]. Moreover, at the present time of manuscript, the FDA has approved anti-PD-1/PD-L1 therapy for four histologic types of cancer: melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and metastatic urothelial carcinoma, all of which are epithelial carcinoma \[[@R5]\].

Almost each of PD-1/PD-L1 blockades has satisfying overall response rates in treating different types of epithelial carcinoma \[[@R6], [@R7]\]. However, the outcome of patients treated with PD-1/PD-L1 blockades is still undetermined, for results of several relevant trials show insignificant improvement in prolonging overall survival (OS) and progression free survival (PFS). Besides, it is still urgently necessary to determine which specific group of patients will benefit from the anti-PD-1/PD-L1 therapy. Most of the present systematic studies focus on the response rate and safety of PD-1/PD-L1 blockades or perform single-arm meta-analyses to evaluate the biomarkers. We conduct the systematic analyses with strictly selected randomized controlled trials to clarify the efficacy and factors indicating the outcome of anti-PD-1/PD-L1 treatment, compared to other controlled interventions within epithelial carcinoma patients by analyzing HRs for OS or PFS.

In consideration of predictive factors, we analyze different membranous PD-L1 expression levels, because PD-L1 expression of tumor cells is most abundant in epithelial carcinoma and most closely correlated with response to anti-PD-1/PD-L1 agents \[[@R5], [@R8], [@R9]\]. Besides, baseline characteristics including age, sex and Eastern Cooperative Oncology Group (ECOG) score are the candidate factors to explore and subgroup analyses of squamous cancer, smoking status, *EGFR* mutation (within NSCLC patients) and *BRAF* mutation (within melanoma patients) are also conducted to provide further evidence for clinical treatment.

RESULTS {#s2}
=======

Study identification {#s2_1}
--------------------

According to the outlined search strategy, a total of 820 records were obtained, of which 371 duplicates were removed. After screening, 484 articles including reviews, case reports and non randomized controlled trials were excluded. Of the rest 19 records, 8 studies did not report the relevant data. Upon the remaining 11 studies, the two reviewers had the perfect agreement on their eligibility and assessed the quality of included studies independently by the scoring criteria stated in *Cochrane handbook for systematic reviews of interventions*. The study selection process was presented in Figure [1](#F1){ref-type="fig"}. The risk of bias graph and summary of selected studies generated by Revman.5.3 were showed in Figure [2](#F2){ref-type="fig"}.

![Flowchart of study selection procedure](oncotarget-07-74350-g001){#F1}

![Risk of bias graph and summary of included clinical trials](oncotarget-07-74350-g002){#F2}

Characteristics of studies {#s2_2}
--------------------------

The analyses were based on data from a total of 6716 patients enrolled in 11 randomized controlled trials. The experimental treatment drugs of those trials were PD-1/PD-L1 blockades, including nivolumab, pembrolizumab and atezolizumab, while the controlled interventions were standard chemotherapy (docetaxel, dacarbazine, etc), targeted therapeutic agents (everolimus) and other form of immunotherapy (ipilimumab). According to currently completed trials focused on epithelial carcinoma, all randomized controlled trials were conducted within melanoma, NSCLC and RCC patients. 6 of the enrolled trials were in melanoma patients (*n* = 3510), 4 in NSCLC patients (*n* = 2385), and 1 in RCC patients (*n* = 821). 3 of the trials were phase 2 trials, 1 was phase 2/3 trial, and 7 were phase 3 trials.

We collected the basic characteristics of patients in each included trial and extracted information to obtain hazard ratios (HRs) for OS and PFS of patients. For the PD-L1 expression evaluation, the immunohistochemistry assays of PD-L1 employed in the selected studies contained Dako, clone 28-8 (Epitomic) and 22C3 antibody (Merck). We retrieved the corresponding HR estimates with the cut-off of 1%, which meant membranous PD-L1 staining in at least 1% of tumor cells. The information of included studies\' authors, cancer types, numbers of patients, interventions, basic characteristics of patients, and HRs for OS and PFS of PD-1/PD-L1 treatment *versus* non-PD-1/PD-L1 therapy were summarized in Table [1](#T1){ref-type="table"}.

###### The patients\' characteristics and outcomes data of clinical trials included

  First author     Year   Total   Intervention                   Cancer type   Med age   Sex (male\[%\])   Harzard Ratio (95%CI)   Ref            
  ---------------- ------ ------- ------------------------------ ------------- --------- ----------------- ----------------------- -------------- ------------
  J Brahmer        2015   272     nivolumab 3mg/kg 2wk           NSCLC         62        82                0.59                    0.62           \[[@R23]\]
                                  docetaxel 75 mg/m^2^ 3wk                     64        71                (0.44, 0.79)            (0.47,0.81)    
  H. Borghaei      2015   792     nivolumab 3mg/kg 2wk           NSCLC         61        52                0.73                    0.92           \[[@R24]\]
                                  docetaxel 75mg/m^2^ 3wk                      64        58                (0.60, 0.89)            (0.77, 1.10)   
  R S Herbst       2016   1034    pembrolizumab 2 mg/kg          NSCLC         63        62                0.71                    0.88           \[[@R25]\]
                                  pembrolizumab 10 mg/kg                       65        62                (0.58, 0.88)            (0.74, 1.05)   
                                  docetaxel                                    62        61                0.61                    0.79           
                                                                                                           (0.49, 0.75)            (0.66, 0.94)   
  L Fehrenbacher   2016   287     atezolizumab 1200 mg           NSCLC         62        65                0.73                    0.94           \[[@R26]\]
                                  docetaxel 75 mg/m^2^ 3wk                     143       53                (0.53, 0.99)            (0.72, 1.23)   
  J. Larkin        2015   945     nivolumab 3mg/kg 2wk           melanoma      59        63.9              0.65                    0.57           \[[@R10]\]
                                  nivolumab 1mg/kg 3wk +                       59        65.6              (0.39, 1.08)            (0.43, 0.76)   
                                  ipilimumab 3mg/kg 3wk                                                                                           
                                  ipilimumab 3mg/kg 3wk                        61        64.1                                                     
  C. Robert        2015   418     nivolumab 3mg/kg 2wk           melanoma      64        57.6              0.42                    0.43           \[[@R27]\]
                                  dacarbazine 1000 mg/m^2^ 3wk                 66        60.1              (0.25, 0.73)            (0.34, 0.56)   
  C. Robert        2015   834     pembrolizumab 10 mg/kg 2wk     melanoma      61        57.7              0.63                    0.58           \[[@R28]\]
                                  pembrolizumab 10mg/kg 3wk                    63        62.8              (0.47, 0.83)            (0.46, 0.72)   
                                  ipilimumab 3mg/kg 3wk                        62        58.3              0.69                    0.58           
                                                                                                           (0.52, 0.90)            (0.47, 0.72)   
  M A. Postow      2015   142     nivolumab 1 mg/kg+             melanoma      64        66                N/A                     0.40           \[[@R29]\]
                                  ipilimumab 3mg/kg                                                                                (0.23, 0.68)   
                                  ipilimumab 3mg/kg                            67        68                                        0.38           
                                                                                                                                   (0.15,1.00)    
  A Ribas          2015   540     pembrolizumab 2 mg/kg 3wk      melanoma      62        58                N/A                     0.57           \[[@R30]\]
                                  pembrolizumab 10mg/kg 3wk                    60        60                                        (0.45, 0.73)   
                                  IC chemotherapy                              63        64                                        0.50           
                                                                                                                                   (0.39, 0.64)   
  J S Weber        2015   631     Nivolumab 3mg/kg 2wk           melanoma      59        65                N/A                     0.82           \[[@R31]\]
                                  IC chemotherapy                              62        64                                        (0.40,1.66)    
  R. J. Motzer     2015   821     nivolumab 3mg/kg 2wk           RCC           62        77                0.73                    0.88           \[[@R32]\]
                                  everolimus 10mg                              62        74                (0.60, 0.89)            (0.75, 1.03)   

Meta-analyses results {#s2_3}
---------------------

The data available on OS pooling were from 10 observations. The pooled HR for OS (Table [2](#T2){ref-type="table"}) was 0.67, (95%CI, 0.62, 0.73; *p* \< 0.001) without significant heterogeneity (I^2^ \< 0.1%), which reflected that compared to non-PD-1/PD-L1 therapy, PD-1/PD-L1 blockades reduced 33% in risk of death among epithelial carcinoma patients. This benefit had met the criteria of treatment superiority.

###### the pooled results of HRs for OS and PFS of the included trials

  Outcome endpoint     Cancer Type   Subgroup           Number of observations   Publication bias (*P*\>\|t\|)\*   HR, (95%CI)          *p*     Pooling model   I^2^%
  -------------------- ------------- ------------------ ------------------------ --------------------------------- -------------------- ------- --------------- -------
  OS                   All types     \--                10                       0.064                             0.67, (0.62, 0.73)   0.000   Fixed           0.0
  OS                   All types     PD-L1                                                                                                      Fixed           
  expression≥1%        5             0.929              0.58, (0.50, 0.66)       0.000                             5.6                                          
  PD-L1                5             0.046              0.75, (0.63, 0.89)       0.001                             0.0                                          
  expression\<1%                                                                                                                                                
  OS                   All types     Age≥65             5                        0.291                             0.72, (0.64, 0.82)   0.000   Fixed           0.0
  Age\<65              7             0.857              0.70, (0.60, 0.81)       0.000                             0.0                                          
  OS                   All types     Male               5                        0.366                             0.68, (0.60, 0.77)   0.000   Fixed           0.0
  Female               5             0.775              0.75, (0.64, 0.88)       0.000                             0.0                                          
  OS                   All types     ECOG score=0       4                        0.181                             0.67, (0.56, 0.80)   0.000   Fixed           0.0
  ECOG score=1         4             0.829              0.69, (0.60, 0.80)       0.000                             0.0                                          
  OS                   NSCLC         Squamous           3                        0.865                             0.67, (0.54, 0.82)   0.000   Fixed           0.0
  Non-squamous         3             0.162              0.69, (0.60, 0.79)       0.000                             0.0                                          
  OS                   NSCLC         *EGFR* wild type   2                        \--                               0.66, (0.57, 0.77)   0.000   Fixed           0.0
  *EGFR* mutant type   2             \--                1.40, (0.92, 2.12)       0.114                             67.3                                         
  OS                   NSCLC         Smoker             2                        \--                               0.71, (0.60, 0.86)   0.000   Fixed           0.0
  Never-Smoker         2             \--                0.88, (0.59, 1.32)       0.536                             39.0                                         
  PFS                  All types     \--                15                       0.063                             0.66, (0.57, 0.76)   0.000   Random          79.7
  PFS                  Melanoma      \--                9                        0.668                             0.54, (0.49, 0.59)   0.000   Fixed           0.0
  NSCLC                5             0.488              0.84, (0.77, 0.92)       0.000                             44.4                                         
  RCC                  1             \--                0.84, (0.75, 1.03)       0.114                             \--                                          
  PFS                  All types     PD-L1                                                                                                      Fixed           
  expression≥1%        3             0.183              0.59, (0.48, 0.72)       0.000                             0.0                                          
  PD-L1                3             0.236              0.80, (0.59, 1.07)       0.136                             0.0                                          
  expression\<1%                                                                                                                                                
  PFS                  All types     Age≥65             5                        0.050                             0.57, (0.44, 0.74)   0.000   Random          77.6
  Age\<65              5             0.000              0.69, (0.56, 0.84)       0.000                             46.8                                         
  PFS                  All types     Male               5                        0.001                             0.60, (0.49, 0.72)   0.000   Random          54.6
  Female               5             0.073              0.67, (0.51, 0.87)       0.002                             66.3                                         
  PFS                  All types     ECOG score=0       5                        0.541                             0.64, (0.48, 0.84)   0.001   Random          77.3
  ECOG score=1         5             0.028              0.65, (0.56, 0.75)       0.000                             18.4                                         
  PFS                  Melanoma      *BRAF* wild type   5                        0.632                             0.51, (0.45, 0.58)   0.000   Fixed           2.7
  *BRAF* mutant type   6             0.342              0.55, (0.44, 0.69)       0.000                             8.0                                          

All studies reported the data on PFS, and the combined HR for PFS with 15 records was 0.66, (95%CI, 0.57, 0.76; *p* \< 0.001). However, a considerable heterogeneity with I^2^ = 79.7 % was observed with the random effect model (Figure [3A](#F3){ref-type="fig"}). Hence, we conducted the subgroup analyses to investigate the cause of heterogeneity and divided the studies into different cancer types (melanoma, NSCLC and RRC). The results of different types analyses had moderate within-group heterogeneities with I^2^ \< 0.1% for melanoma and 44% for NSCLC. The computed HRs (95%CI; p) for PFS in melanoma, NSCLC and RCC were 0.54 (0.49, 0.59; *p* \< 0.001), 0.84 (0.77, 0.92; *p* \< 0.001), 0.84 (0.75, 1.03; *p* = 0.114) respectively.

![Forest plots of A. hazard ratio (HR) for PFS; B. HRs for PFS in subgroups of different types of epithelial carcinoma](oncotarget-07-74350-g003){#F3}

To investigate predictive role of PD-L1 expression, we computed the aggregated HRs for OS and PFS in different levels of PD-L1 expression ( ≥ 1%, \< 1%) groups and generated the forest plot (Figure [4](#F4){ref-type="fig"}). Pooled HRs (95%CI; p) were 0.58, (0.50, 0.66; *p* \< 0.001) in PD-L1 ≥ 1% group, 0.75, (0.63, 0.89; *p* = 0.001) in PD-L1 \< 1% group for OS and 0.59, (0.48, 0.72; *p* \< 0.001) in PD-L1 ≥ 1% group, 0.80, (0.59, 1.07; *p* = 0.136) in PD-L1 \< 1% group for PFS with not important heterogeneity within all subgroups (I^2^ = 5.6%,0.0%,0.0%,0.0%).

![Forest plots of HRs for OS and PFS in the subgroups of patients with PD-L1 expression ≥ 1% and \< 1%](oncotarget-07-74350-g004){#F4}

We also analyzed the baseline data such as age, sex and ECOG score of 0 or 1 (on a 5-point scale, with higher scores indicating greater disability) to further explore other factors. The results of pooled HRs for OS and PFS corresponding to these factors were listed in Table [2](#T2){ref-type="table"} and the effects of anti-PD-1/PD-L1 therapy in all those subgroups were favorable and did not have significantly changes between different ages, sexes and ECOG scores groups.

Among the NSCLC patients, both the squamous patients (HR (95%CI) = 0.67, (0.54, 0.82); *p* \< 0.001) and non-squamous patients (0.69, (0.60, 0.79); *p* \< 0.001) had more extended OS when compared with non-PD-1/PD-L1 therapy. In *EGFR* wild type patients, the HR for OS was 0.66, (0.57, 0.77); *p* \< 0.001, indicating the better efficacy of PD-1/PD-L1 blockades in those patients. However, in patients with *EGFR* mutant type, the HR for OS was 1.40, (0.92, 2.12) and p was 0.114 (I^2^of heterogeneity = 67.3%), suggesting that anti-PD-1/PD-L1 therapy functioned not distinctly better than the control group treatment. Similarly, the never-smokers were verified not to have the expectedly longer OS with HR pooled as 0.88, (0.59, 1.32); *p* = 0.536 with I^2^ = 39.0%. The HR for OS in smokers was 0.71, (0.60, 0.86); *p* \< 0.001 with the meaning of better outcomes due to the use of anti-PD-1/PD-L1 agents. Besides, in melanoma patients, both the *BRAF* wild type and *BRAF* mutant patients benefited in OS, and HRs (95%CIs) were 0.51, (0.45, 0.58), *p* \< 0.001; 0.55, (0.44, 0.69), *p* \< 0.001 respectively with not important heterogeneity (I^2^ = 2.7%; I^2^ = 8.0%) (Figure [5](#F5){ref-type="fig"}).

All reported data of the meta-analyses results were listed in Table [2](#T2){ref-type="table"} with the relative details and models adopted.

![Forest plots of HRs for OS in squamous, non-squamous, *EGFR* mutant, *EGFR* wild, Smoker and never smoker NSCLC subgroup patients](oncotarget-07-74350-g005){#F5}

Sensitivity analyses {#s2_4}
--------------------

The sensitivity analyses were conducted by excluding studies one by one. The results of those analyses showed no significant differences when compared to the former summary estimates and had excellent stability.

Publication bias {#s2_5}
----------------

We assessed the publication bias of included data for pooled analyses using the Egger\'s test, and the p values were listed in Table [2](#T2){ref-type="table"}. In the light of data computed and listed, there was no substantial publication bias (*p* \< 0.05) in our main analyses. Nevertheless, two possible biases with *p* \< 0.05 by Egger\'s test were observed in the subgroups of Age \< 65 and Male patients in the pooling process of HR for PFS.

DISCUSSION {#s3}
==========

It was acknowledged that PD-1/PD-L1 blockade, as a type of immune checkpoint inhibitors, had remarkable response rate and clinical results in patients with different kinds of cancer, especially those with epithelial-originated malignancies. Nonetheless, it remained unclear whether anti-PD-1/PD-L1 therapy, in contrast with other therapy, functioned better to extend OS and PFS and which subgroups of patients would benefit from the treatment. Our meta-analysis integrating all data from relevant trials were requested to solve the problem. To our knowledge, the meta-analysis was the first study to investigate the outcome and predictive biomarkers for PD-1/PD-L1 therapy in epithelial carcinoma patients within solely randomized controlled trials by assessing the two primary endpoints of OS and PFS.

Our results provided convincing evidence that the OS of patients given PD-1/PD-L1 inhibitors was significantly longer than patients given other drugs as those individual studies reported (only one study comparing nivolumab with ipilimumab (CTLA-4 antibody) \[[@R10]\] excluded). The effect of PD-1/PD-L1 inhibitors on prolonging PFS was controversial among the 15 observations from 11 enrolled trials and our aggregated HR affirmed the efficacy to extend PFS in epithelial carcinoma patients. However, the heterogeneity of the studies was significant and we conducted the subgroup analyses stratified by different cancer types to figure out this issue. The results of subgroup analyses indicated that both the melanoma and NSCLC patients could obtain longer PFS due to the use of PD-1/PD-L1 blockades. Whilst HR for PFS in one RCC trial suggested that no difference in PFS between the two interventions existed.

In PD-L1 expression investigation, we found it not practicable to use PD-L1 as a biomarker to predict OS benefit when comparing PD-1/PD-L1 blockades with other control therapy, for both the higher (PD-L1 expression ≥ 1%) and lower (PD-L1 expression \< 1%) expression groups could gain obvious clinical benefit from PD-1/PD-L1 blockades. Be that as it may, the higher expression group had the better PFS outcome, but the lower expression group was associated with insubstantial improvement of PFS. The immunohistochemistry (IHC) cut-off value (ranging from 1% to 50%) we chose to define the PD-L1 positivity was 1%, in that the clinical data assessed by this point were the most abundant in the included 11 trials. Besides, cutting off by the lowest expression level enabled to include the most possible patients who could benefit from the therapy. However, the assessment of PD-L1 expression was much complicated because the tumor PD-L1 expression was not constant which was associated with activated tumor antigen-specific T cells \[[@R11], [@R12]\] and could be induced by specific agents such as interferon \[[@R13]\]. In addition, the degree of PD-L1 expression could be heterogeneous between different types of cancer or even primary and metastatic lesions in one type of cancer \[[@R12]\]. As for detection methods, there were still many limitations of IHC detection such as the low efficacy caused by the two small hydrophilic regions of PD-L1 antibody and the bias caused by different proprietary assays in different trials \[[@R14], [@R15]\]. Several associations were focusing on standardizing and validating a reliable IHC assay of PD-L1 expression currently \[[@R16]\]. The combination of IHC and gene amplification as the detection method adopted in HER-2 status assessment in gastric and breast cancers \[[@R17], [@R18]\] also gave the instruction for PD-L1 detection \[[@R19], [@R20]\]. Thus, the further experiments focused on the expression mechanism and detection were needed to draw more definitive conclusion.

The next novel finding of our analyses was in different subgroups. We found that the *BRAF* mutant or *BRAF* wild type patients in melanoma group, and the squamous cancer patient or non-squamous cancer patients in NSCLC group had gained better outcome of survival. But there was no significant improvement for OS in patients without smoking history and patients with *EGFR* mutations. Whilst, the present or previous smoker, patients with *EGFR* wild type showed longer survival time, implicating the smoking history and *EGFR* wild type might be considered as the potential predictive factors for anti-PD-1/PD-L1 treatment. In our speculation, the association of mutations and other exposures to mutagens like smoking with the efficacy of PD-L1 blockades was possibly because the tumor antigen, considered as the target of T cell activated by checkpoint blockade, was related to the consequence of somatic mutations \[[@R19], [@R21], [@R22]\]. However, the limited number of observations in our subgroup analyses still required prospective validation with larger scale investigations.

Finally, OS had been improved in the overall patient regardless of the age, sex and ECOG score. Thus, it was persuasive that those factors were not meaningful indicators for the eligibility of anti-PD-1/PD-L1 treatment.

In conclusion, the aggregated HRs for OS and PFS summarized in our systematic analyses revealed that in the comparison of anti-PD-1/PD-L1 agents with other control therapy, the PD-L1 expression was not an appropriate factor to predict the benefit of OS in epithelial carcinoma patients, but could be predictive for PFS. Age, sex and ECOG score were excluded to predict any of the outcome endpoints. Smoking history and *EGFR* wild type were potential indicators for prolonged OS in NSCLC patients. There were multiple clinical trials ongoing and many other antibodies targeting PD-1/PD-L1 under early-stage development currently, more comprehensive data from future clinical trials focused on this field were still needed for further investigation.

MATERIALS AND METHODS {#s4}
=====================

Publications search {#s4_1}
-------------------

We searched for the articles of clinical trials from PubMed, Embase, Web of Science, and the Cochrane Library from January 2010 to April 2016. Records at American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the world Conference of Lung cancer (WCLC) were also reviewed. The following search terms were used: "pembrolizumab", "Nivolumab" "atezolizumab", "Tremelimumab", "AMP-224", "MDX-1105", "pidilizumab", and "cancer/carcinoma".

Study selection {#s4_2}
---------------

All relevant articles underwent evaluation for eligibility by two investigators independently and we selected the articles according to the following criteria: 1) articles with randomized controlled trials (RCTs); 2) at least one of the two endpoints (PFS, OS) reported; 3) published in English; 4) the full text available. Our exclusion criteria were as below: 1) letters, expert opinions, case reports and reviews; 2) articles without available data; 3) duplicate publications.

Quality assessment {#s4_3}
------------------

We assessed the quality of involved randomized controlled clinical trials according to the criteria presented in the *Cochrane Handbook for Systematic Reviews of Interventions* (version 5.1.0; chapter 8), and evaluated the random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias to ensure the low-risk of bias of the studies included.

Data extraction {#s4_4}
---------------

The data of study identification, the intervention of experimental treatment and control group, numbers of enrolled patients in each trial, patients\' detailed information (age, sex, line of therapy and ECOG score), hazard ratios(HR) with their 95%CIs and p values for OS and PFS were extracted by two individual investigators independently. We also collected the relevant information in every subgroup we set to render sufficient data to our subgroup analyses.

Statistical analysis {#s4_5}
--------------------

We calculated pooled HRs and their 95%CIs for OS and PFS which were considered to be the primary outcome of the meta-analyses and generated the forest plots accordingly. The chi-square Q test and I^2^ statistic were used to indicate the heterogeneity. A p value less than 0.05 in the Q test or an I^2^ value greater than 50% in the I^2^ statistics suggested the significant heterogeneity. If the heterogeneity was significant, we used the random effect model of pooling instead of fixed effect model and designed subgroups analyses to clarify the between-study heterogeneity. To test the publication bias of the included studies, the Egger\'s test was chosen. All the statistical analyses were performed with STATA/SE software version12.0 (STATA Corporation, College Station, TX, USA).
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